ERBB2 and breast carcinoma: On the other hand, even if SIRT6 loss has been reported to induce Trastuzumab-resistance in HER2-overexpressing breast cancer26, very little is known about the real role of SIRT6 in this breast cancer subtype that represents about 30% of all mammary tumor cases.